ADRB2 and amyloidosis: Specific microglial β2-AR deletion worsened AD pathology in the 5xFAD mouse model, while chronic β2-AR stimulation resulted in attenuation of amyloid pathology and associated neuritic damage, suggesting microglial β2-AR might be used as a potential therapeutic target to modify AD pathology [10,66].